These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37788005)

  • 1. Identification and validation of obesity related genes signature based on microenvironment phenotypes in prostate adenocarcinoma.
    Liang L; Shang J; Zhang Y; Xu Y; Zhouteng Y; Wen J; Zhao Y; Feng N; Zhao R
    Aging (Albany NY); 2023 Oct; 15(19):10168-10192. PubMed ID: 37788005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
    Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
    Front Immunol; 2022; 13():964393. PubMed ID: 36211344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
    Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
    Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
    Xu Z; Chen S; Zhang Y; Liu R; Chen M
    Front Immunol; 2022; 13():869759. PubMed ID: 35603206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.
    Chen L; Zhang M; Zhou J; Zhang L; Liang C
    Cancer Med; 2022 Nov; 11(22):4374-4388. PubMed ID: 35535438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
    Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
    Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
    Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
    Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
    Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
    Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma.
    Liu J; Tan Z; Yang S; Song X; Li W
    Aging (Albany NY); 2022 Sep; 14(17):7170-7185. PubMed ID: 36103249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of metabolism-associated molecular patterns in prostate cancer.
    Yang B; Jiang Y; Yang J; Zhou W; Yang T; Zhang R; Xu J; Guo H
    BMC Urol; 2023 Jun; 23(1):104. PubMed ID: 37280589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.
    Zhao HB; Zeng YR; Han ZD; Zhuo YJ; Liang YK; Hon CT; Wan S; Wu S; Dahl D; Zhong WD; Wu CL
    Cancer Sci; 2021 Oct; 112(10):4365-4376. PubMed ID: 34252262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Database Mining of Genes of Prognostic Value for the Prostate Adenocarcinoma Microenvironment Using the Cancer Gene Atlas.
    Zhao X; Hu D; Li J; Zhao G; Tang W; Cheng H
    Biomed Res Int; 2020; 2020():5019793. PubMed ID: 32509861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for prostate adenocarcinoma.
    Liang L; Xia W; Yao L; Wu Q; Hua L; Cheng G; Wang Z; Zhao R
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108267. PubMed ID: 34740081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel stemness-related signature with appealing implications in discriminating the prognosis and therapy responses for prostate cancer.
    Zhang T; Li J; Dai J; Yuan F; Yuan G; Chen H; Zhu D; Mao X; Qin L; Liu N; Yang M
    Cancer Genet; 2023 Aug; 276-277():48-59. PubMed ID: 37487324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration.
    Piao S; Zheng L; Zheng H; Zhou M; Feng Q; Zhou S; Ke M; Yang H; Wang X
    J Immunol Res; 2022; 2022():2922832. PubMed ID: 35707002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
    Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X
    Front Immunol; 2023; 14():1126902. PubMed ID: 36891298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A N
    Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L
    J Oncol; 2022; 2022():8604216. PubMed ID: 35602299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
    Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
    Front Immunol; 2021; 12():791924. PubMed ID: 34975891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
    Luo Y; Liu X; Lin J; Zhong W; Chen Q
    Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.